BIOMAT Database Logo BIOMAT Database Logo

Combination therapy of a solid murine tumor with 1, 3 bis (2-chloroethyl)-1-nitrosourea and irradiation. 1979

A C Begg, and K K Fu, and J Vennari, and T L Phillips

UI MeSH Term Description Entries
D008297 Male Males
D008325 Mammary Neoplasms, Experimental Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS. Experimental Mammary Neoplasms,Neoplasms, Experimental Mammary,Experimental Mammary Neoplasm,Mammary Neoplasm, Experimental,Neoplasm, Experimental Mammary
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D002330 Carmustine A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) BCNU,1,3-Bis(2-Chloroethyl)-1-Nitrosourea,BiCNU,FIVB,N,N'-Bis(2-Chloroethyl)-N-Nitrosourea,Nitrumon
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014185 Transplantation, Isogeneic Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains. Transplantation, Syngeneic,Isogeneic Transplantation,Isograft Transplantation,Isografting,Syngeneic Transplantation,Transplantation, Isograft

Related Publications

A C Begg, and K K Fu, and J Vennari, and T L Phillips
[Experience with combination therapy of solid tumors using 1-(2-chloroethyl)-3-cyclohexyl-nitrosourea--CCNU].
January 1980, Giornale italiano di chemioterapia,
A C Begg, and K K Fu, and J Vennari, and T L Phillips
Reactions of 1,3-bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in aqueous solution.
October 1979, Journal of medicinal chemistry,
A C Begg, and K K Fu, and J Vennari, and T L Phillips
Combination therapy of solid tumors using 1,3-bis(2-chloroethyl)-1-nitrosourea (NCNU), vincristine, methotrexate, and 5-fluorouracil.
June 1973, Cancer,
A C Begg, and K K Fu, and J Vennari, and T L Phillips
1,-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (methyl CCNU) and adriamycin combination therapy.
November 1974, Cancer,
A C Begg, and K K Fu, and J Vennari, and T L Phillips
Inhibition of human glutathione reductase by the nitrosourea drugs 1,3-bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-3-(2-hydroxyethyl)-1-nitrosourea. A crystallographic analysis.
January 1988, European journal of biochemistry,
A C Begg, and K K Fu, and J Vennari, and T L Phillips
Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma.
October 1979, Blood,
A C Begg, and K K Fu, and J Vennari, and T L Phillips
Sensitivity of human and murine hematopoietic precursor cells to 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose and 1,3-bis(2-chloroethyl)-1-nitrosourea.
February 1978, Cancer research,
A C Begg, and K K Fu, and J Vennari, and T L Phillips
Pulmonary fibrosis after prolonged therapy with 1,3-bis (2-chloroethyl)-1-nitrosourea.
September 1977, Chest,
A C Begg, and K K Fu, and J Vennari, and T L Phillips
5-Fluorouracil, 1,3-bis(2-chloroethyl)-1-nitrosourea, and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea: effect on the human granulopoietic system.
April 1982, Journal of the National Cancer Institute,
A C Begg, and K K Fu, and J Vennari, and T L Phillips
Nitrosoureas: 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962; BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC-79037; CCNU)--clinical brochure.
December 1968, Cancer chemotherapy reports. Part 3,
Copied contents to your clipboard!